



PATENT
Attorney Docket No. UM-08477

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shaomeng Wang *et al.*

Serial No.: 10/729,156

Group No.: 1614

Filed: 12/05/2003

Examiner: Hui

Entitled: Small Molecule Antagonists of BCL-2 Family Proteins

**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT TRANSMITTAL**


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 C.F.R. ? 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 21, 2007

By:



Mary Ellen Waite

Sir or Madam:

Enclosed please find a Supplemental Information Disclosure Statement and Form PTO-1449, including copy of the reference contained thereon, for filing in the U.S. Patent and Trademark Office.

Applicant's believe no fee is required. If the Commissioner deems otherwise, the Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. **An originally executed duplicate of this transmittal is enclosed for this purpose.**

Dated: March 21, 2007



Robert A. Goetz
Registration No. 55,210

MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900



PATENT
Attorney Docket No. UM-08477

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Shaomeng Wang *et al.*

Serial No.: 10/729,156

Group No.: 1614

Filed: 12/05/2003

Examiner: Hui

Entitled: **Small Molecule Antagonists of BCL-2 Family Proteins**

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT


Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: March 21, 2007

By:


Mary Ellen Waite

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- CN 1406919
- CN 87105990
- CN 1033795
- CN 1094392

- DE 1917341
- JP 01132542
- RU 2067111
- SU 212245
- SU 322042

- Becattini et al., Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL; *Chem Biol* 11:389 (2004)
- Brzezinski et al., Selective Esterification of Gossypol by Copper Acetate in Acetonitrile-Spectroscopic Studies; *Spectroscopy Lett* 27:1143 (1994)
- Dowd et al., Crystal and Molecular Structure of an Enantiomeric Gossypol-Acetic Acid Clathrate; *J Am Oil Chem Soc* 76:1343 (1999)
- Dowd et al., A Correction to the Molecular Structure of Enantiomeric Gossypol; *J Am Oil Chem Soc* 78:1171 (2001)
- Dowd et al., The Gossypol-Cyclododecanone (1/2) inclusion Complex; *Acta Crystallogr C* 59:397 (2003)
- Dowd et al., The (-) –Gossypol-2,4-pentanedione (1:2) inclusion complex; *J Chem Crystallogr* 34:559 (2004)
- Freedman et al., Determination of the Absolute Configuration and Solution Conformation of Gossypol by Vibrational Circular Dichroism; *Chirality* 15:196 (2003)
- Gdaniec et al., Gossypol; *Comprehensive Supramolecular Chemistry* 6:117-200
- Gonzalez Correa et al., New Gossypol Derivatives; *J Am Oil Chem Soc* 43: 678 (1966)
- Han, X Y Jie He Za Zhi 2:159 (1982 (Chinese)
- Hei et al., Electron Microscope Examination of Biopsy of Testis Tissue from the Patients with Tumors after Oral Treatment with Gossypol; *Acta Acad Med Sinicae* 61:527 (1981) (Chinese with Translation)


- Jaroszewski et al., Effects of Gossypol on Drug-Sensitive and Drug-Resistant Cancer Cells; Proc Am Assoc Cancer Res 31:377 (1990)
- Kable et al., Potency, Selectivity and Cell Cycle Dependence of Catechols in Human Tumour Cells In Vitro; Biochem Pharmacol 37:1711 (1988)
- Kim et al., Gossypol, a Hyperthermic Sensitizer of HeLa Cells; Cancer Res 45:6338 (1985)
- Liu et al., The (-)-Enantiomer of Gossypol Possesses Higher Anticancer Potency than Racemic Gossypol in Human Breast Cancer; Anticancer Res 22:33 (2002)
- McClarty et al., Ribonucleotide Reductase: A Intracellular Target for the Male Antifertility Agent, Gossypol; Biochem Biophys Res Commun 133:300 (1985)
- Miller et al., Structure of Gossypol. IV. Anhydrogossypol and its Derivatives; J Am Chem Cos 59:1736 (1937)
- Molla et al., Influence of 5-Hydroxytryptamine on the Combination Effect of Lonidamine or Gossypol and Hyperthermia on Ehrlich Tumour In Vivo; Anticancer Res 7:361 (1987)
- Senzer, Hyperthermia: Chemotherapeutic and biologic response Modifications; Strahlenther Onkol 165:729 (1989)
- Tripathy et al., Gossypol Effects on Breast Cancer Oncogene Expression and Membrane Receptor Signal Transduction; Breast Cancer Res Treat 16:160 (1990)
- Vermel, The Search for Antitumour Substances of Plant Origin; Acta Unio Internationalis Contra Cancrum 20:211 (1964)
- Vermel et al., Voprosy Oncologii 10:88 (1964) (Russian)
- Xu, A Laboratory Investigation on the Antitumor Effects of Gossypol; Med J Jinan Univ 2:39 (1987) (Chinese with translation)
- Zakhidov et al., Ezvestiia Akademii Nauk SSSR Seria Biologicheskaiia 4:694 (1994) (Russian)
- Zhang et al., Comparison of the Killing Effect of Levorotatory, Dextrorotatory and Recemic Gossypol on HeLa Cells; Acta Acad Med Sinicae 7:384 (1985) (Chinese with translation)

- Zhang et al., Analysis of the Possible Mechanism of the Cytotoxic Effect of Gossypol in Mice, Rats and Human Tumor Cell Lines; Acta Acad Med Sinicae 8:486 (1986) (Chinese with translation)
- Zhang et al., In Vitro Antiproliferative Effect of Two New Platinum-Containing Bile Acid Derivatives: Bamet-U2 and Bamet-D3; Anticancer Res 18:4807 (1998)
- Zhang et al., Differential Proliferative Responses to the (-)-enantiomer of Gossypol in Cultured Human Breast Epithelial and Stromal Cells; Proc Amer Assoc Cancer Res 40:4 (1999)

This application was filed after June 30, 2003. Therefore, pursuant to the waiver of the requirements under 37 CFR 1.98(a)(2)(i), copies of each U.S. Patent and each U.S. Patent Application Publication are not required to be submitted. Copies of any foreign patent documents and non-patent literature cited herein are enclosed.

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: 3-21-2007



Robert A. Goetz
Registration No. 55,210
MEDLEN & CARROLL, LLP
101 Howard Street, Suite 350
San Francisco, California 94105
608/218-6900

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1

of

Complete if Known:

Application Number	10/729,156
Filing Date	12/05/2003
First Named Inventor	Wang et al.
Art Unit	1614
Examiner Name	Hui

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	1	CN 1406919 /	09/06/2001		entire document	
	2	CN 87105990 /	12/26/1987		entire document	
	3	CN 1033795	12/07/1989		entire document	
	4	CN 1094392	11/02/1994		entire document	
	5	DE 1917341 /			entire document	
	6	JP 01132542	04/03/1969		entire document	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Shee

1 of

Complete if Known

Application Number	10/729,156
Filing Date	12/05/2003
First Named Inventor	Wang et al.
Art Unit	1614
Examiner Name	Hui
Attorney Docket Number	UM-08477

U. S. PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)			
	7	RU 2067111			entire document
	8	SU 212245			entire document
	9	SU 322042			entire document

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/729,156
				Filing Date	12/05/2003
				First Named Inventor	Wang et al.
				Art Unit	1614
				Examiner Name	Hui
Sheet	3	of		Attorney Docket Number	UM-08477

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	10	Becattini et al., Rational Design and Real Time, In-Cell Detection of the Proapoptotic Activity of a Novel Compound Targeting Bcl-XL; Chem Biol 11:389 (2004)			
	11	Brzezinski et al., Selective Esterification of Gossypol by Copper Acetate in Acetonitrile-Spectroscopi Studies; Spectroscopy Lett 27:1143 (1994)			
	12	Dowd et al., Crystal and Molecular Structure of an Enantiomeric Gossypol-Acetic Acid Clathrate; J Am Oil Chem Soc 76:1343 (1999)			
	13	Dowd et al., A Correction to the Molecular Structure of Enantiomeric Gossypol; J Am Oil Chem Soc 78:1171 (2001)			
	14	Dowd et al., The Gossypol-Cyclododecanone (1/2) inclusion Complex; Acta Crystallogr C 59:397 (2003)			/
	15	Dowd et al., The (-) -Gossypol-2,4-pentanedione (1:2) inclusion complex; J Chem Crystallogr 34:559 (2004)			/
	16	Freedman et al., Determination of the Absolute Configuration and Solution Conformation of Gossypol by Vibrational Circular Dichroism; Chirality 15:196 (2003)			/
	17	Gdaniec et al., Gossypol; Compregensive Supramolecular Chemistry6:117-200			
	18	Gonzalez Correa et al., New Gossypol Derivatives; J Am Oil Chem Soc 43: 678 (1966)			
	19	Han, X Y Jie He Za Zhi 2:159 (1982 (Chinese)			

Examiner Signature		Date Considered	
---------------------------	--	------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 4

of

Application Number	10/729,156
Filing Date	12/05/2003
First Named Inventor	Wang et al.
Art Unit	1614
Examiner Name	Hui

Attorney Docket Number UM-08477

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	20	Hei et al., Electron Microscope Examination of Biopsy of Testis Tissue from the Patients with Tumors after Oral Treatment with Gossypol; Acta Acad Med Sinicae 61:527 (1981) (Chinese with Translation)	/
	21	Jaroszewski et al., Effects of Gossypol on Drug-Sensitive and Drug-Resistant Cancer Cells; Proc Am Assoc Cancer Res 31:377 (1990)	
	22	Kable et al., Potency, Selectivity and Cell Cycle Dependence of Catechols in Human Tumour Cells In Vitro; Biochem Pharmacol 37:1711 (1988)	
	23	Kim et al., Gossypol, a Hyperthermic Sensitizer of HeLa Cells; Cancer Res 45:6338 (1985)	
	24	Liu et al., The (-)-Enantiomer of Gossypol Possesses Higher Anticancer Potency than Racemic Gossypol in Human Breast Cancer; Anticancer Res 22:33 (2002)	
	25	McClarty et al., Ribonucleotide Reductase: A Intracellular Target for the Male Antifertility Agent, Gossypol; Biochem Biophys Res Commun 133:300 (1985)	
	26	Miller et al., Structure of Gossypol. IV. Anhydrogossypol and its Derivatives; J Am Chem Cos 59:1736 (1937)	
	27	Molla et al., Influence of 5-Hydroxytryptamine on the Combination Effect of Lonidamine or Gossypol and Hyperthermia on Ehrlich Tumour In Vivo; Anticancer Res 7:361 (1987)	
	28	Senzer, Hyperthermia: Chemotherapeutic and biologic response Modifications; Strahlenther Onkol 165:729 (1989)	
	29	Tripathy et al., Gossypol Effects on Breast Cancer Oncogene Expression and Membrane Receptor Signal Transduction; Breast Cancer Res Treat 16:160 (1990)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Complete if Known**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

Attorney Docket Number

UM-08477

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	30	Vermel, The Search for Antitumour Substances of Plant Origin; Acta Unio Internationalis Contra Cancrum 20:211 (1964)	
	31	Vermel et al., Voprosy Oncologii 10:88 (1964) (Russian)	
	32	Xu, A Laboratory Investigation on the Antitumor Effects of Gossypol; Med J Jinan Univ 2:39 (1987) (Chinese with translation)	
	33	Zakhidov et al., Ezvestiia Akademii Nauk SSSR Seriia Biologicheskaiia 4:694 (1994) (Russian)	
	34	Zhang et al., Comparison of the Killing Effect of Levorotatory, Dextrorotatory and Recemic Gossypol on HeLa Cells; Acta Acad Med Sinicae 7:384 (1985) (Chinese with translation)	
	35	Zhang et al., Analysis of the Possible Mechanism of the Cytotoxic Effect of Gossypol in Mice, Rats and Human Tumor Cell Lines; Acta Acad Med Sinicae 8:486 (1986) (Chinese with translation)	
	36	Zhang et al., In Vitro Antiproliferative Effect of Two New Platinum-Containing Bile Acid Derivatives: Bemet-U2 and Bemet-D3; Anticancer Res 18:4807 (1998)	
	37	Zhang et al., Differential Proliferative Responses to the (-)-enantiomer of Gossypol in Cultured Human Breast Epithelial and Stromal Cells; Proc Amer Assoc Cancer Res 40:4 (1999)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.